VTGN
WatchlistVistaGen Therapeutics, Inc.
Healthcare · NASDAQ
$18.8M mkt cap
Brief updated Jun 16, 2026
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neur
VTGN faces growth scrutiny
VistaGen Therapeutics is a clinical-stage biopharmaceutical company with a 5314.0% revenue growth rate. Its conviction score is 36/100, indicating a cautious outlook. The company's net margin is -5491.0%, raising concerns about its financial sustainability. The analyst consensus rating is HOLD, reflecting uncertainty about its prospects.
Why now
The current market volatility, with the Dow dropping 400 points, highlights the need for close scrutiny of VTGN's growth prospects. The company's revenue growth rate and significant net margin losses make it a high-risk, high-reward investment opportunity.
Key risks
Valuation risk is a major concern, given VTGN's negative P/E ratio of -0.3x and significant net margin losses. Execution risk is also a factor, as the company's ability to commercialize its pipeline, including PH94B, is uncertain. Macro risk, driven by US-Iran tensions, may also impact the company's prospects.
What to watch
Investors should monitor VTGN's upcoming financial reports to assess its ability to maintain revenue growth and improve its net margin. The company's progress in commercializing its pipeline, particularly PH94B, will be a key indicator of its future prospects over the next 1-3 quarters.
Stock Market Today: Dow Drops 400 Points, Small Caps Crater On U.S.-Iran Unease; Macy's Wobbles (Live Coverage)
The Dow Jones dropped 400 points and small caps declined significantly due to rising tensions between the U.S. and Iran, sparking geopolitical uncertainty and risk-off sentiment in the markets. This escalation has the potential to impact global markets and asset classes.
Jun 3, 2026
SLB N.V. (SLB): A Top Oil Stock to Buy amid US-Iran War on Expected Growth
The US-Iran conflict is escalating, which could lead to increased geopolitical risk and potentially disrupt oil supplies, making SLB N.V. a potentially attractive investment due to expected growth.
Jun 3, 2026
Update: WTI Oil Rises Again as the United States and Iran Trade Strikes
The United States and Iran have engaged in trade strikes, leading to a rise in WTI oil prices as geopolitical tensions escalate in the region. This conflict has the potential to disrupt global oil supplies and impact markets.
Jun 3, 2026
Oil Rises Again as the United States and Iran Trade Strikes
The United States and Iran have engaged in a series of military strikes, leading to increased tensions in the Middle East and a subsequent rise in oil prices. This conflict has the potential to disrupt global oil supplies and impact the broader macro environment.
Jun 3, 2026
Earnings surprises
-27.6%
2026-06
+11.8%
2026-02
-5.9%
2025-11
—
2025-08
+17.3%
2025-06
Generated Tue, 16 Jun 2026 05:07:04 GMT by Decifer intelligence engine. For informational purposes only — not investment advice. Decifer Intelligence Hub.